<DOC>
	<DOCNO>NCT00078338</DOCNO>
	<brief_summary>The primary objective study assess clinical efficacy Rebif® 44 mcg three time per week compare Copaxone® 20 mg daily patient relapse Multiple Sclerosis .</brief_summary>
	<brief_title>Rebif® Versus Copaxone® Treatment Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Be 18 60 year age . Have definite relapse multiple sclerosis . Have one relapse within prior 12 month . Must clinically stable improve neurological state four week prior Study Day 1 . EDSS score 0 5.5 , inclusive If female , must either postmenopausal surgically sterilize ; use hormonal contraceptive , intra uterine device , diaphragm spermicide , condom spermicide , duration study ; neither pregnant breastfeeding . Confirmation subject pregnant must establish negative serum hCG pregnancy test within 7 day Study Day 1 negative urine pregnancy test Study Day 1 . A pregnancy test require subject postmenopausal surgically sterilize . Be willing able comply protocol duration study Voluntarily provide write informed consent , USA sit , subject authorization Health Insurance Portability Accountability Act ( HIPAA ) , prior studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Have secondary progressive MS primary progressive MS . Prior use interferon glatiramer acetate . Have treatment oral systemic corticosteroid ACTH within 4 week Study Day 1 within 7 day prior Day 1 MRI . Have psychiatric disorder unstable would preclude safe participation study . Have significant leukopenia ( white blood cell count &lt; 0.5 time low limit normal central laboratory ) within 7 day Study Day 1 . Have elevate liver function test ( AST , ALT , alkaline phosphatase &gt; 2.0 time upper limit normal ( ULN ) central laboratory , total bilirubin &gt; 1.5 time ULN central laboratory ) within 7 day Study Day 1 history hepatitis ( include infectious druginduced ) . Prior cytokine anticytokine therapy within 3 month prior Study Day 1 . Prior use immunomodulatory immunosuppressive therapy ( include limit cyclophosphamide , cyclosporin , methotrexate , azathioprine , linomide , mitoxantrone ) within 12 month prior Study Day 1 . Prior use cladribine receive total lymphoid irradiation . Have allergy hypersensitivity human serum albumin , mannitol , glatiramer acetate , natural recombinant interferonβ , component study drug gadolinium DTPA . Have take intravenous immunoglobulin investigational drug take part experimental procedure 6 month prior Study Day 1 . Presence systemic disease might interfere subject safety , compliance evaluation condition study ( e.g . insulindependent diabetes , Lyme disease , clinically significant cardiac disease , HIV , HTLV1 ) . Have plasma exchange 3 month prior Study Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>